Sign in

Martin Hoenigl

@martinhoenigl.bsky.social
1.1K followers 185 following 28 posts

Tenure Track Prof for Translational Mycology, Medical University Graz, Austria; Past President ECMM.❤️for Clinical Mycology, ⬛⬜1909 ⚽️ Rams 🏈#StandwithUkraine

PostsRepliesMedia
Martin Hoenigl @martinhoenigl.bsky.social · 14/05/2026
Antifungal resistance is growing – will new treatments turn the tables. Very happy to be featured in this important Nature outlook alongside many icons of the Mycology field. www.nature.com/articles/d41...
nature.com
Antifungal resistance is growing – will new treatments turn the tables?
Trials of drugs to fight deadly resistant infections are advancing, but they might fall victim to overuse of agricultural fungicides just like their predecessors.
000
Reposted by Martin Hoenigl
ecmmcandidaiv.bsky.social @ecmmcandidaiv.bsky.social · 13/04/2026
Excited to share our new publication: Clinical Characteristics, Management and Outcomes of Non-ICU Candidemia – a subanalysis of the ECMM Candida III multinational European cohort study. 😊 academic.oup.com/ofid/article... @martinhoenigl.bsky.social @olivercornely.bsky.social
academic.oup.com
Clinical Characteristics, Management and Outcomes of Nonintensive Care Unit Candidemia: Subanalysis of the ECMM Candida III Multinational European Observational Cohort Study
A subanalysis of 396 candidemia cases diagnosed outside the intensive care unit from the pan-European multicenter ECMM Candida III study showed higher surv
022
Reposted by Martin Hoenigl
GALActIC @galactic-europe.bsky.social · 13/04/2026
Incidence and outcomes of influenza-associated pulmonary aspergillosis and the role of antifungal prophylaxis: a structured literature review link.springer.com/article/10.1... @martinhoenigl.bsky.social @agocarvalho.bsky.social @simonfeys.bsky.social
link.springer.com
Incidence and outcomes of influenza-associated pulmonary aspergillosis and the role of antifungal prophylaxis: a structured literature review - Critical Care
Critical Care - Influenza-associated pulmonary aspergillosis (IAPA) is a frequent and often fatal complication of severe influenza in critically ill patients. Despite increased recognition, its...
022
Martin Hoenigl @martinhoenigl.bsky.social · 28/03/2026
Incidence and outcomes of influenza-associated pulmonary aspergillosis and the role of antifungal prophylaxis: a structured literature review Work informing aims of @galactic-europe.bsky.social Comgrats to all involved. rdcu.be/fazXN
rdcu.be
Incidence and outcomes of influenza-associated pulmonary aspergillosis and the role of antifungal prophylaxis: a structured literature review
041
Martin Hoenigl @martinhoenigl.bsky.social · 28/03/2026
Clinical characteristics, management and outcomes of non-ICU candidemia: Sub-analysis of the ECMM Candida III multinational European observational cohort study url: academic.oup.com/ofid/article...
academic.oup.com
Clinical characteristics, management and outcomes of non-ICU candidemia: Sub-analysis of the ECMM Candida III multinational European observational cohort study
Abstract. ECMM-Candida III was a pan-European, multicentre observational study of adult patients with blood culture-proven candidemia. Among a total of 632
010
Martin Hoenigl @martinhoenigl.bsky.social · 22/03/2026
Mapping the landscape of endemic mycoses in India: Insights from a systematic review of reported cases spanning six decades (1960-2025) @ofidjournal.bsky.social @drarghadip.bsky.social @grthompsonmd.bsky.social url: academic.oup.com/ofid/article...
academic.oup.com
Mapping the landscape of endemic mycoses in India: Insights from a systematic review of reported cases spanning six decades (1960-2025)
AbstractBackground. Endemic mycoses are caused by fungi inhabiting specific ecological niches. These infections remain underdiagnosed and underreported due
021
Reposted by Martin Hoenigl
Open Forum Infectious Diseases @ofidjournal.bsky.social · 08/01/2026
Mucorales PCR testing in Respiratory and Biopsy Samples from Immunocompromised Patients with Invasive Pulmonary Aspergillosis and other Mold Infections: Results from a Multicenter ECMM Study ✅ Just Accepted bit.ly/3NxZoD2
bit.ly
Mucorales PCR testing in Respiratory and Biopsy Samples from Immunocompromised Patients with Invasive Pulmonary Aspergillosis and other Mold Infections: Results from a Multicenter ECMM Study
Mucormycosis is a severe fungal infection that is challenging to diagnose as traditional methods lack sensitivity and serological testi
033
Martin Hoenigl @martinhoenigl.bsky.social · 17/03/2026
Evidence that increased azole persistence and stress resistance precede the in vivo evolution of azole resistance in Aspergillus fumigatus | Microbiology Spectrum journals.asm.org/doi/10.1128/...
journals.asm.org
011
Martin Hoenigl @martinhoenigl.bsky.social · 04/03/2026
Treatment Monitoring and Outcome Prediction in Invasive Aspergillosis using Immunologic. Results of an ECMM multicenter study. Big 🙏 to all involved and driving this project @agocarvalho.bsky.social and many more Markers url: academic.oup.com/jid/article/...
academic.oup.com
Treatment Monitoring and Outcome Prediction in Invasive Aspergillosis using Immunologic Markers
This multicenter study evaluated circulating immune biomarkers in patients with invasive aspergillosis to monitor treatment and predict outcome. Several pr
000
Martin Hoenigl @martinhoenigl.bsky.social · 01/03/2026
Diagnostic accuracy of Mucorales PCR testing in bronchoalveolar lavage fluid samples: a retrospective analysis of a prospectively collected cohort - Clinical Microbiology and Infection www.clinicalmicrobiologyandinfection.org/article/S119...
clinicalmicrobiologyandinfection.org
Diagnostic accuracy of Mucorales PCR testing in bronchoalveolar lavage fluid samples: a retrospective analysis of a prospectively collected cohort
To evaluate the diagnostic performance, particularly specificity, of the MucorGenius® PCR assay for detecting pulmonary mucormycosis in bronchoalveolar lavage fluid (BALF) samples from at-risk patient...
000
Martin Hoenigl @martinhoenigl.bsky.social · 01/03/2026
Rapid and reliable diagnosis of mucormycosis using colorimetric loop-mediated isothermal amplification | Journal of Clinical Microbiology @ecmmcandidaiv.bsky.social @galactic-europe.bsky.social journals.asm.org/doi/10.1128/...
journals.asm.org
Rapid and reliable diagnosis of mucormycosis using colorimetric loop-mediated isothermal amplification | Journal of Clinical Microbiology
Mucormycosis is a rapidly progressive and fatal fungal infection. Timely diagnosis is critical for effective treatment, yet current diagnostic tools are slow, insensitive, or require complex laborator...
022
Reposted by Martin Hoenigl
Steven Pergam, MD, MPH @pergamic.bsky.social · 30/01/2026
Upcoming @idsainfo.bsky.social Immunocompromised Host COP and @msgerc.bsky.social webinar: Feb 10, 2026 10:00 AM Central "Testing Rationally in Mycology: Using Fungal Diagnostics to Drive Better Antifungal Decisions" Sign up here: societycentral.zoom.us/webinar/regi...
063
Reposted by Martin Hoenigl
Mycoses Study Group Education & Research Consortium @msgerc.bsky.social · 19/01/2026
New webinar on fungal diagnostics! Link in next post
224
Reposted by Martin Hoenigl
ecmmcandidaiv.bsky.social @ecmmcandidaiv.bsky.social · 13/01/2026
Update on Candida IV study at #TIMM2025 Still open for registration 🔬🧫🧪 Join now!
021
Martin Hoenigl @martinhoenigl.bsky.social · 08/01/2026
academic.oup.com/ofid/advance...
academic.oup.com
Mucorales PCR testing in Respiratory and Biopsy Samples from Immunocompromised Patients with Invasive Pulmonary Aspergillosis and other Mold Infections: Results from a Multicenter ECMM Study
AbstractBackground. Mucormycosis is a severe fungal infection that is challenging to diagnose as traditional methods lack sensitivity and serological testi
000
Reposted by Martin Hoenigl
Oliver Cornely @olivercornely.bsky.social · 05/12/2025
Early mycological clearance in uncomplicated candidaemia can improve outcomes, reduce ICU stay, and lower healthcare costs. Timely antifungal therapy is key. Read more: doi.org/10.1111/myc.... @martinhoenigl.bsky.social #Candidaemia #AntifungalTherapy #InfectiousDiseases #ICU #Healthcare
doi.org
The Importance of Early Mycological Clearance of Uncomplicated Candidaemia and Its Implications for Clinical Practice
Invasive candidiasis is a life-threatening infection associated with high morbidity, mortality and healthcare costs in both general and critical care settings. Timely diagnosis and adequate antifunga....
0118
Martin Hoenigl @martinhoenigl.bsky.social · 22/10/2025
link.springer.com/article/10.1... rdcu.be/eL6ug
link.springer.com
Invasive candidiasis in intensive care medicine: shaping the future of diagnosis and therapy - Intensive Care Medicine
Background Invasive candidiasis (IC) remains one of the most challenging infections in critical care, contributing significantly to morbidity, prolonged organ support, and mortality among intensive ca...
000
Reposted by Martin Hoenigl
Young ISHAM @youngisham.bsky.social · 03/10/2025
2025 #Candida #Guidelines by ECMM, ISHAM, ASM + Summary recs here; full evidence, methods + pediatric guidance in appendix. www.thelancet.com/journals/lan... @olivercornely.bsky.social @martinhoenigl.bsky.social @anaalastruey.bsky.social @germhuntermd.bsky.social @fhagen.bsky.social
153
Reposted by Martin Hoenigl
GALActIC @galactic-europe.bsky.social · 03/10/2025
GALActIC Project – EU Collaboration Against IAPA | Consortium Meeting on Future Planning in Bilbao 🇪🇸 Galactic Europe: lnkd.in/d77xessA @martinhoenigl.bsky.social @simonfeys.bsky.social @agocarvalho.bsky.social
lnkd.in
LinkedIn
This link will take you to a page that’s not on LinkedIn
121
Reposted by Martin Hoenigl
Sarah Dellière @sarah-delliere.bsky.social · 04/09/2025
✨📄 What about the untapped therapeutic potential of the immune response in invasive aspergillosis ? Here’s some rational, pre-clinical and clinical evidence. Huge thanks to our amazing 🌍 team! 🔗 bit.ly/46kajHr @simonfeys.bsky.social @agocarvalho.bsky.social @martinhoenigl.bsky.social
0159
Martin Hoenigl @martinhoenigl.bsky.social · 18/06/2025
🔥🗞️Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study. Groundbreaking work on a very promising new antifungal. Free access here: authors.elsevier.com/c/1lHca5E-Uo...
authors.elsevier.com
031
Reposted by Martin Hoenigl
Norman van Rhijn @normanvanrhijn.bsky.social · 12/06/2025
🚨Our latest review in Thorax about the impact of climate change focusing on fungal pathogens in Europe 🌍 A truly enjoyable collaboration with Sarah Sedik @germhuntermd.bsky.social @martinhoenigl.bsky.social and @mbottery.bsky.social thorax.bmj.com/content/earl...
02714
Reposted by Martin Hoenigl
Ilan Schwartz @germhuntermd.bsky.social · 08/06/2025
Addressing Antifungal Drug Resistance — A “One Health–One World” Challenge @grthompsonmd.bsky.social and Angel Desai www.nejm.org/doi/full/10....
nejm.org
Addressing Antifungal Drug Resistance — A “One Health–One World” Challenge | NEJM
Use of some antifungal pesticides may select for resistant fungi in the environment, which can then endanger human health. Coordinated regulatory processes in this area are important.
0228
Reposted by Martin Hoenigl
Ilan Schwartz @germhuntermd.bsky.social · 09/06/2025
Climate change: shifting boundaries of fungal disease in Europe and beyond New review in Thorax by @mbottery.bsky.social Sarah Sedik @germhuntermd.bsky.social @martinhoenigl.bsky.social @normanvanrhijn.bsky.social thorax.bmj.com/content/thor... #MedSky #IDSky #PulmSky #ClimateSky #MedMycoSky
Health risks with environmental changes and mould exposure. Key impacts of flooding include increased precipitation, rising sea levels and land use changes, leading to indoor mould growth and health risks such as respiratory issues, asthma exacerbation and mould infections. Case studies highlight varying health outcomes from Hurricane Katrina and Rita (2005), Colorado Flood (2013) and Hurricane Harvey (2017). Drivers of emerging fungal pathogens in a changing world. Climate change factors, such as rising temperatures and increasing resistance to fungicides, enhance fungal thermotolerance and drive the emergence of pathogens. Social determinants, including urbanisation, global travel and limited healthcare access, heighten human vulnerability to fungal infections. Other contributing factors, like environmental niches and unconfirmed environmental sources, further support the spread and persistence of fungal pathogens. These drivers contribute to the emergence of pathogens like Candida auris, Candida orthopsilosis and Cryptococcus deuterogatii. Climate change and antifungal resistance: key mechanisms and pathogen examples. Climate change drives the development of antifungal resistance through mechanisms such as environmental pollution with fungicides, prolonged heat stress and increased mutation rates in fungi. These conditions promote genetic mutations, increased resistance to antifungal drugs and more challenging infections in humans and plants
12917
Reposted by Martin Hoenigl
Ilan Schwartz @germhuntermd.bsky.social · 03/06/2025
Diagnosis and Management of Candida Endophthalmitis and Chorioretinitis Nate Permpalung, Sarah Sedik, Pete Pappas, @martinhoenigl.bsky.social, @drluiso.bsky.social in @cmijournal.bsky.social www.clinicalmicrobiologyandinfection.com/article/S119...
clinicalmicrobiologyandinfection.com
Diagnosis and Management of Candida Endophthalmitis and Chorioretinitis
Candida endophthalmitis and chorioretinitis are uncommon but potentially devastating complications of candidemia, associated with significant risks of vision loss and long-term morbidity. Effective ma...
196
Reposted by Martin Hoenigl
ecmmcandidaiv.bsky.social @ecmmcandidaiv.bsky.social · 23/05/2025
Proud to present the progress of ECMM Candida IV study at #ISHAM2025 Still open for participation! @martinhoenigl.bsky.social
042
Reposted by Martin Hoenigl
Oliver Cornely @olivercornely.bsky.social · 22/05/2025
Yesterday at ISHAM 2025, Danila Seidel explored how environmental extremes can spark fungal outbreaks 🌪️🌱 A powerful reminder of climate’s role in emerging mycoses. #ISHAM2025 #FungalOutbreaks #ClimateAndHealth #MedicalMycology
1209
Reposted by Martin Hoenigl
Dr Neil Stone @drneilstone.bsky.social · 22/05/2025
Did you know..75% of wine has significant levels of azole antifungals in it? (German wine anyway) Potential consequences for driving resistance... #IDSky #ISHAM
54511
Reposted by Martin Hoenigl
Arghadip Samaddar, MD @drarghadip.bsky.social · 22/05/2025
Happy to meet some wonderful colleagues & brilliant minds in Medical Mycology. @martinhoenigl.bsky.social @germhuntermd.bsky.social at #ISHAM2025 It has been an amazing congress with enriching academic sessions, lovely food & great hospitality at such a captivating location @fozdoiguacu.bsky.social
241
Reposted by Martin Hoenigl
Oliver Cornely @olivercornely.bsky.social · 09/05/2025
Thrilled to see Dr. Jon Salmanton-García receive the GEMICOMED Young Researcher Award 2025! His impactful research on invasive fungal & viral infections in hematologic malignancies is shaping the future of mycology: www.journalofinfection.com/article/S016... #FungalResearch #Mycology
184
Reposted by Martin Hoenigl
ecmmcandidaiv.bsky.social @ecmmcandidaiv.bsky.social · 24/04/2025
Exciting news! The ECMM Candida IV study is now featured on the ECMM website! Find all the details here: www.ecmm.info/working-grou... @martinhoenigl.bsky.social
ecmm.info
Antifungal tolerance, resistance and clinical outcomes on candidemia caused by non-albicans Candida  - ECMM
ECMM Candida IV Antifungal tolerance, resistance and clinical outcomes on candidemia caused by non-albicans Candida  Observation periods/Timeline Observation period: April 1st, 2024 – September 30th, ...
053
Martin Hoenigl @martinhoenigl.bsky.social · 20/04/2025
Sampling different types of grains at local markets in Namibia starting our project Fungal diversity of processed staple cereals from rural subsistence farming communities in Namibia 🙏🏻🙏🏻to colleagues from University of Namibia for hosting me
050
Reposted by Martin Hoenigl
Oliver Cornely @olivercornely.bsky.social · 13/04/2025
Honored to present today at ESCMID Global in Vienna: Ibrexafungerp salvage results from 233 patients in the FURI study — showing high success rates! 🔬💪 A promising new tool in the antifungal pipeline. #ESCMID2025 #FURIstudy #Ibrexafungerp #Antifungals #InfectiousDiseases
0245
Reposted by Martin Hoenigl
ecmmcandidaiv.bsky.social @ecmmcandidaiv.bsky.social · 08/04/2025
ECMM Candida IV Study is still open for participation Global study on non-albicans candidemia Requirements: 🔬Clinical data + isolates (no limit per site) 📅Apr 2024-Sep 2025 📦Ship isolates in one batch at study end 💰Case-based reimbursement available @martinhoenigl.bsky.social
076
Martin Hoenigl @martinhoenigl.bsky.social · 02/04/2025
👉Participate in the ECMM Candida IV Study 🌍wide study on candidemia caused by non-albicans Candida Requirement: clinical data & isolate (not req for C.auris) Observation period: 04/2024 - 09/2025 Interested? Email stella.wolfgruber@medunigraz.at
033
Reposted by Martin Hoenigl
GALActIC @galactic-europe.bsky.social · 02/04/2025
On April 1, 2025, our project officially started. A significant milestone that we have worked towards for a long time. Now, we look forward to taking the next steps together. @martinhoenigl.bsky.social @simonfeys.bsky.social @agocarvalho.bsky.social
152
Martin Hoenigl @martinhoenigl.bsky.social · 02/04/2025
Projekt „GALActIC“ startet: Biomarker für Pilzinfektionen erforscht www.medunigraz.at/news/detail/...
medunigraz.at
Projekt „GALActIC“ startet: Biomarker für Pilzinfektionen erforscht
Eine internationale Studie unter Beteiligung der Med Uni Graz erforscht bestimmte Biomarker im Zusammenhang mit Pilzinfektionen.
021
Reposted by Martin Hoenigl
ICVS - Life and Health Sciences Research Institute | UMinho @icvs-uminho.bsky.social · 31/03/2025
🔬💡 ICVS Researchers Join Innovative GALActIC Study to Combat IAPA! Researchers of the I3D team are part of this European project, aiming to improve the identification and treatment of Influenza-associated Pulmonary Aspergillosis and enhance patient care! 🙌 More at: icvs.uminho.pt/icvs-researc...
093
Reposted by Martin Hoenigl
Don Vinh @donvinh.bsky.social · 20/03/2025
A potentially new antifungal class: Mandimycin, polyene-like but targeting phospholipids, rather than ergosterol. ✅activity against yeasts in vivo 🐁 With insights from @olivercornely.bsky.social @martinhoenigl.bsky.social & David Denning www.science.org/content/arti...
science.org
Deadly fungi are becoming drug-resistant. A new compound could beat them
A drug candidate with a new mechanism of action shows promise against several drug-resistant infections in mice
03511
Martin Hoenigl @martinhoenigl.bsky.social · 19/03/2025
Deadly fungi are becoming drug-resistant. A new compound could beat them | Science | AAAS @kakape.bsky.social www.science.org/content/arti...
science.org
Deadly fungi are becoming drug-resistant. A new compound could beat them
A drug candidate with a new mechanism of action shows promise against several drug-resistant infections in mice
042
Reposted by Martin Hoenigl
Oliver Cornely @olivercornely.bsky.social · 18/03/2025
🔬 New research highlights a potential game-changer in treating invasive mould infections! 🦠 Patients show increased PD-1 expression, suggesting immune checkpoint inhibitors could help fight these deadly infections. More studies needed! 💡 onlinelibrary.wiley.com/doi/10.1111/... #Immunotherapy
onlinelibrary.wiley.com
Immune Phenotypes in Patients With Invasive Mould Infection Support the Use of PD‐1 Inhibition as Potential Treatment Option
Background Invasive mould infections (IMI) cause substantial morbidity and mortality in populations at risk. Novel treatment approaches are urgently needed. Targeting immune checkpoints may reverse ...
074
Reposted by Martin Hoenigl
GALActIC @galactic-europe.bsky.social · 17/03/2025
New Medical Study Starting Soon 🔬 The logo was designed in collaboration with Galactic Partners, with professional support from Esra Sedik. Follow us for more! @martinhoenigl.bsky.social @agocarvalho.bsky.social @simonfeys.bsky.social
164
Reposted by Martin Hoenigl
Ilan Schwartz @germhuntermd.bsky.social · 11/03/2025
Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter PK study for Screening Antifungal Exposure in Intensive Care Units (SAFE-ICU) J Roberts etc TLDR: ++variable, need tailored approach w TDM link.springer.com/article/10.1...
AUC0-24/MIC for two different durations of antifungal treatment in ICU: 1-3 days vs 4-7 days, shown for various antifungals (and for caspofungin and anidulafungin shown separately for C albicans and C glabrata)

PK/PD target-related exposures per occasion of the study antifungals prescribed for treatment. The shaded area represents the PK/PD target used in this study. For fluconazole, 15 data points are outside the y-axis limits (max AUC0-24/MIC value was 3250.3); ICU intensive care unit; AUC0-24 area under the plasma concentration-time curve from zero to 24 h; fAUC0-24 free AUC0-24; MIC minimum inhibitory concentration; Cmin minimum observed plasma concentration; Cmax maximum observed plasma concentration
0184
Reposted by Martin Hoenigl
ESCMID Fungal Infection Study Group (EFISG) @efisg-escmid.bsky.social · 10/03/2025
🌍 Fungal Care Gaps: Brazil vs. Europe 🇧🇷➡️🇪🇺 Fungal infections are a global challenge with uneven access to diagnostic and treatment. Europe has more labs, better tests, and antifungal access, while Brazil faces greater threats from Cryptococcus and Histoplasma. journals.asm.org/doi/epub/10....
journals.asm.org
Elevating fungal care: bridging Brazil’s healthcare practices to global standards
033
Reposted by Martin Hoenigl
Luis Ostrosky, MD, FIDSA @drluiso.bsky.social · 03/03/2025
It’s out! A pleasure to work with @alukmd.bsky.social on the latest #fungal update of the ID Clinics of North America. I rembember saving money as a med student to buy them… #FullCircle #IDSky #MedSky
2233
Reposted by Martin Hoenigl
Open Forum Infectious Diseases @ofidjournal.bsky.social · 02/03/2025
Prevalence of injecting-related bacterial and fungal infection among people who inject drugs: a systematic review and meta-analysis ✅ Just Accepted #IDSky
buff.ly
Prevalence of injecting-related bacterial and fungal infection among people who inject drugs: a systematic review and meta-analysis
Despite increasing burden of injecting-related bacterial and fungal infection, there has been no recent synthesis of their epidemiology. We performed a systematic review and meta-analysis evaluating prevalence and incidence of injecting-related infection among people who inject drugs.
253
Reposted by Martin Hoenigl
Science Friday @scifri.bsky.social · 28/02/2025
Despite being vastly outnumbered by bacteria, fungi in our microbiome still play a significant role in our health. In today’s episode, we learn about the “mycobiome.” Plus, turmoil at the NIH. Listen here 🎧: buff.ly/4ii9d2g
782492
Martin Hoenigl @martinhoenigl.bsky.social · 01/03/2025
Antifungal pipeline: New tools for the treatment of mycoses. Focus on LMICs where many dont have access to current antifungals. Updated maps on fungal availability in LMICS. Thanks to a fantastic group of authors www.sciencedirect.com/science/arti...
sciencedirect.com
Antifungal pipeline: New tools for the treatment of mycoses
Fungal infections are becoming an escalating public health challenge, particularly among immunocompromised individuals. The partially limited efficacy…
043
Reposted by Martin Hoenigl
Ilan Schwartz @germhuntermd.bsky.social · 24/02/2025
Fungal Infections in People Who Use Drugs Jose Portugal Gonzales & @drluiso.bsky.social academic.oup.com/ofid/advance...
academic.oup.com
Fungal Infections in People Who Use Drugs
Abstract. Illicit drug use in the United States continues to rise, alongside an increasing number of severe infections associated with drug use. Surveillan
12313